These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8067766)

  • 41. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group.
    Sullam PM; Gordin FM; Wynne BA
    Clin Infect Dis; 1994 Jul; 19(1):84-6. PubMed ID: 7948562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
    Tomioka H; Saito H; Fujii K; Sato K; Hidaka T
    Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
    Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Difference in drug susceptibility distribution and clinical characteristics between
    Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
    J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
    [No Abstract]   [Full Text] [Related]  

  • 45. Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method.
    Marone P; Bono L; Carretto E; Barbarini D; Telecco S
    J Chemother; 1997 Aug; 9(4):247-50. PubMed ID: 9269603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.
    Carter G; Young LS; Bermudez LE
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4907-10. PubMed ID: 15561879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS.
    Siegal FP
    Clin Infect Dis; 1996 Apr; 22 Suppl 1():S23-30; discussion S30-2. PubMed ID: 8785252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.
    Peloquin CA
    Clin Pharmacokinet; 1997 Feb; 32(2):132-44. PubMed ID: 9068928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MAC prophylaxis revisited.
    Torres G
    GMHC Treat Issues; 1996 Apr; 10(4):6-7, 10. PubMed ID: 11363706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disseminated Mycobacterium avium complex disease in patients with AIDS.
    Benson C
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):913-6. PubMed ID: 7811542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.
    Perronne C; Gikas A; Truffot-Pernot C; Grosset J; Pocidalo JJ; Vilde JL
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1508-11. PubMed ID: 2171421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
    Barrett MS; Jones RN; Erwin ME; Koontz FP
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimycobacterial synergism of clarithromycin and rifabutin.
    Ghebremichael S; Svenson SB; Källenius G; Hoffner SE
    Scand J Infect Dis; 1996; 28(4):387-90. PubMed ID: 8893404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of antimicrobial agents against Mycobacterium avium-intracellulare complex (MAC) strains isolated in Italy from AIDS-patients.
    Fattorini L; Hu CQ; Jin SH; Santoro C; Tsang AY; Mascellino MT; Mandler F; Orefici G
    Zentralbl Bakteriol; 1992 Apr; 276(4):512-20. PubMed ID: 1611208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antivirals key to MAC prevention regimen.
    AIDS Alert; 1996 Sep; 11(9):101-3. PubMed ID: 11363722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Present status and future prospects of chemotherapeutics for intractable infections due to Mycobacterium avium complex.
    Tomioka H
    Curr Drug Discov Technol; 2004 Dec; 1(4):255-68. PubMed ID: 16472242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials.
    Miltner EC; Bermudez LE
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1990-4. PubMed ID: 10858369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group.
    Dubé MP; Torriani FJ; See D; Havlir DV; Kemper CA; Leedom JM; Tilles JG; McCutchan JA; Sattler FR
    Clin Infect Dis; 1999 Jan; 28(1):136-8. PubMed ID: 10028084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current strategies for the prevention and treatment of disseminated Mycobacterium avium complex infection in patients with AIDS.
    Wright J
    Pharmacotherapy; 1998; 18(4):738-47. PubMed ID: 9692648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
    Huang CC; Wu MF; Chen HC; Huang WC
    J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.